Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms Following Vaccination | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: June 26, 2021.

Published Online: August 16, 2021. doi:10.1001/jamainternmed.2021.4580

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Debes AK et al. JAMA Internal Medicine.

Corresponding Author: Amanda K. Debes, PhD, MS, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, E5036, Baltimore, MD 21205 (adebes1@jhu.edu).

Author Contributions: Dr Milstone had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Debes, Colantuoni, Egbert, Caturegli, Milstone.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Debes, Xiao, Colantuoni, Egbert.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Debes, Xiao, Colantuoni, Caturegli.

Obtained funding: Milstone.

Administrative, technical, or material support: Debes, Egbert, Caturegli, Gadala.

Supervision: Colantuoni, Milstone.

Conflict of Interest Disclosures: Dr Milstone reported receiving grant support from Merck outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported in part by the National Institutes of Health under award No. K24AI141580 (Dr Milstone) and through the generosity of the collective community of donors to the Johns Hopkins University School of Medicine and the Johns Hopkins Health System for COVID-19 research.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Additional Contributions: The authors would like to thank LuAnn Rezavi, BS, and Brittney Howard, MS, and other members of the Johns Hopkins Hospital Clinical Immunology Laboratory, Danielle Koontz, MAA, MAS, and Annie Voskertchian, MPH, of the Johns Hopkins Division of Pediatric Infectious Diseases, and Shaun Truelove, PhD, from the Johns Hopkins Bloomberg School of Public Health. They did not receive compensation for these contributions.

References
1.
Manisty  C , Treibel  TA , Jensen  M ,  et al.  Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection.   EBioMedicine. 2021;65:103259. doi:10.1016/j.ebiom.2021.103259PubMedGoogle Scholar
2.
Chu  L , McPhee  R , Huang  W ,  et al; mRNA-1273 Study Group.  A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.   Vaccine. 2021;39(20):2791-2799. doi:10.1016/j.vaccine.2021.02.007PubMedGoogle ScholarCrossref
3.
Chapin-Bardales  J , Gee  J , Myers  T .  Reactogenicity following receipt of mRNA-based COVID-19 vaccines.   JAMA. 2021;325(21):2201-2202. doi:10.1001/jama.2021.5374PubMedGoogle ScholarCrossref
4.
Krammer  F , Srivastava  K , Alshammary  H ,  et al.  Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine.   N Engl J Med. 2021;384(14):1372-1374. doi:10.1056/NEJMc2101667PubMedGoogle ScholarCrossref
5.
Caturegli  G , Materi  J , Howard  BM , Caturegli  P .  Clinical validity of serum antibodies to SARS-CoV-2 : a case-control study.   Ann Intern Med. 2020;173(8):614-622. doi:10.7326/M20-2889PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close